Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
30000 participants
OBSERVATIONAL
2016-01-31
2030-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. to provide and develop a surveillance system to describe clinical practice and temporal changes in the clinical course of HIV and HIV-related co-infections and co-morbidities in France.
2. to assess the factors associated with the clinical, immunological and virological course of HIV infection and HIV-related co-infections and co-morbidities
The specific objectives are as follows
* To continue surveillance of HIV infection in France to describe temporal changes
* To evaluate the efficacy of ART and factors associated with ART efficacy
* To monitor the uptake and outcome of HCV therapy
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Medico-social Description of Seniors Living With HIV, Associated With a Qualitative Survey on Their Care in the Paris Region Structures
NCT05135689
Risk of Morbidity, Mortality and Long-term Monitoring of Antiretroviral Treatment in People Living With HIV
NCT03296202
Older HIV-infected Adults and Drug Interactions: French Cross-sectional Study
NCT03416881
HIV Patients Cohort
NCT02203006
Nice Human Immunodeficiency Virus (HIV) Cohort
NCT03690063
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients without written informed consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
DatAids
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pascal PUGLIESE, MD
Role: PRINCIPAL_INVESTIGATOR
Centre Hospitalier Universitaire de Nice
André CABIE, MD-PhD
Role: PRINCIPAL_INVESTIGATOR
CHU de Martinique
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Nord Franche Comté
Belfort, , France
CHU Besançon - Hôpital Jean Minjoz
Besançon, , France
CHRU Brest
Brest, , France
Centre Hospitalier de Brive
Brive-la-Gaillarde, , France
CHU Clermont-Ferrand - Hôpital Gabriel-Montpied
Clermont-Ferrand, , France
CHIC
Créteil, , France
CHD Vendée
La Roche-sur-Yon, , France
Centre Hospitalier de La Rochelle
La Rochelle, , France
Hôpital Bicêtre - Assistance Publique des Hôpitaux de Paris
Le Kremlin-Bicêtre, , France
CHU Limoges
Limoges, , France
Hôpital de la Croix-Rousse - Hospices Civils de Lyon
Lyon, , France
Hôpital Sainte Marguerite - Assistance Publique des Hôpitaux de Marseille
Marseille, , France
IHU - Assistance Publique des Hôpitaux de Marseille
Marseille, , France
CHR Metz-Thionville
Metz, , France
Hôpital Gui de Chauliac
Montpellier, , France
CHU Nancy - Hôpital Brabois
Nancy, , France
CHU Nantes - Hôtel-Dieu
Nantes, , France
CHU Nice
Nice, , France
Centre Hospitalier de Niort
Niort, , France
CH Nîmes
Nîmes, , France
CHR Orléans
Orléans, , France
Groupe Hospitalier Pitié Salpêtrière - Assistance Publique des Hôpitaux de Paris
Paris, , France
Hôpital Bichat - Assistance Publique des Hôpitaux de Paris
Paris, , France
Hôpital Necker-Pasteur - Assistance Publique des Hôpitaux de Paris
Paris, , France
Centre Hospitalier de Cornouaille
Quimper, , France
CHU Reims - Hôpital Robert Debré
Reims, , France
CHU Rennes - Hôpital Pontchaillou
Rennes, , France
CH Rochefort
Rochefort, , France
CHU Rouen
Rouen, , France
CHU St Etienne - Hôpital Nord
Saint-Etienne, , France
CHU Strasbourg - Hôpital Civil
Strasbourg, , France
CHU Toulouse - Hôpital Purpan
Toulouse, , France
CHU Tourcoing - Hôpital Guy Chatiliez
Tourcoing, , France
CH Troyes
Troyes, , France
CH Bretagne-Atlantique
Vannes, , France
CHIV
Villeneuve-Saint-Georges, , France
CHU de Guadeloupe
Pointe-à-Pitre, , Guadeloupe
CHU de Martinique
Fort-de-France, , Martinique
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Vincent GENDRIN
Role: primary
Catherine CHIROUZE
Role: primary
Sylvain JAFFUEL
Role: primary
Marion GAUDIN
Role: primary
Christine JACOMET
Role: primary
Isabelle DELACROIX
Role: primary
Dominique MERRIEN
Role: primary
Mariam RONCATO
Role: primary
Antoine CHERET
Role: primary
Jean-François FAUCHER
Role: primary
Dulce ALFAIATE
Role: primary
Sylvie BREGIGEON-RONOT
Role: primary
Amélie MENARD
Role: primary
Céline ROBERT
Role: primary
Alain MAKINSON
Role: primary
Benjamin LEFEVRE
Role: primary
Clotilde ALLAVENA
Role: primary
Pascal PUGLIESE
Role: primary
Simon SUNDER
Role: primary
Paul LOUBET
Role: primary
Laurent HOCQUELOUX
Role: primary
Christine KATLAMA
Role: primary
Yazdan YAZDANPANAH
Role: primary
Claudine DUVIVIER
Role: primary
Nolwenn HALL
Role: primary
Firouze BANISADR
Role: primary
Cédric ARVIEUX
Role: primary
Mariam RONCATO
Role: primary
Manuel ETIENNE
Role: primary
Amandine GAGNEUX-BRUNON
Role: primary
Axel URSENBACH
Role: primary
Pierre DELOBEL
Role: primary
Olivier ROBINEAU
Role: primary
Simona PAVEL
Role: primary
Grégory CORVAISIER
Role: primary
Pauline CARAUX-PAZ
Role: primary
Isabelle LAMAURY
Role: primary
André CABIE
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Pugliese P, Cuzin L, Cabie A, Poizot-Martin I, Allavena C, Duvivier C, El Guedj M, de la Tribonniere X, Valantin MA, Dellamonica P; Nadis Group. A large French prospective cohort of HIV-infected patients: the Nadis Cohort. HIV Med. 2009 Sep;10(8):504-11. doi: 10.1111/j.1468-1293.2009.00719.x. Epub 2009 May 19.
Palich R, Hentzien M, Hocqueloux L, Duvivier C, Allavena C, Huleux T, Delobel P, Makinson A, Rey D, Cuzin L; Dat'AIDS Study Group. Country of birth is associated with antiretroviral therapy choice in treatment-naive persons with HIV in France. AIDS. 2023 Jul 15;37(9):1459-1466. doi: 10.1097/QAD.0000000000003588. Epub 2023 Apr 20.
Cuzin L, Allavena C, Cotte L, Delpierre C, Huleux T, Palich R, Delobel P, Raffi F, Cabie A; Dat'AIDS Study Group. No barrier to care, yet disparities in the HIV care continuum in France: a nationwide population study. J Antimicrob Chemother. 2021 May 12;76(6):1573-1579. doi: 10.1093/jac/dkab061.
Cotte L, Hocqueloux L, Lefebvre M, Pradat P, Bani-Sadr F, Huleux T, Poizot-Martin I, Pugliese P, Rey D, Cabie A; Dat'AIDS Study Group. Microelimination or Not? The Changing Epidemiology of Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in France 2012-2018. Clin Infect Dis. 2021 Nov 2;73(9):e3266-e3274. doi: 10.1093/cid/ciaa1940.
Ursenbach A, Max V, Maurel M, Bani-Sadr F, Gagneux-Brunon A, Garraffo R, Ravaux I, Robineau O, Makinson A, Rey D; Dat'AIDS Study Group. Incidence of diabetes in HIV-infected patients treated with first-line integrase strand transfer inhibitors: a French multicentre retrospective study. J Antimicrob Chemother. 2020 Nov 1;75(11):3344-3348. doi: 10.1093/jac/dkaa330.
Le Guillou A, Pugliese P, Raffi F, Cabie A, Cuzin L, Katlama C, Allavena C, Drame M, Cotte L, Bani-Sadr F; Dat'AIDS Study Group. Reaching the Second and Third Joint United Nations Programme on HIV/AIDS 90-90-90 Targets Is Accompanied by a Dramatic Reduction in Primary Human Immunodeficiency Virus (HIV) Infection and in Recent HIV Infections in a Large French Nationwide HIV Cohort. Clin Infect Dis. 2020 Jul 11;71(2):293-300. doi: 10.1093/cid/ciz800.
Gantner P, Cotte L, Allavena C, Bani-Sadr F, Huleux T, Duvivier C, Valantin MA, Jacomet C, Joly V, Cheret A, Pugliese P, Delobel P, Cabie A, Rey D; Dat'AIDS Study Group. Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection. PLoS One. 2019 Apr 18;14(4):e0215464. doi: 10.1371/journal.pone.0215464. eCollection 2019.
Hentzien M, Drame M, Delpierre C, Allavena C, Cabie A, Cuzin L, Rey D, Pugliese P, Hedelin G, Bani-Sadr F; Dat'AIDS Study Group. HIV-related excess mortality and age-related comorbidities in patients with HIV aged >/=60: a relative survival analysis in the French Dat'AIDS cohort. BMJ Open. 2019 Jan 25;9(1):e024841. doi: 10.1136/bmjopen-2018-024841.
Virlogeux V, Zoulim F, Pugliese P, Poizot-Martin I, Valantin MA, Cuzin L, Reynes J, Billaud E, Huleux T, Bani-Sadr F, Rey D, Fresard A, Jacomet C, Duvivier C, Cheret A, Hustache-Mathieu L, Hoen B, Cabie A, Cotte L; Dat'AIDS Study Group. Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination. BMC Med. 2017 Dec 18;15(1):217. doi: 10.1186/s12916-017-0979-1.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DAT_001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.